0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Marizyme
Its shares trade under the ticker MRZM. It has been listed since 5 April 1995. In the fiscal year to 31 December 2024, it reported revenue of $645,810 and a net loss of $69.5m. At that date it held total assets of $22.0m and shareholders' equity of −$6.7m.
Marizyme, Inc. is a biotechnology company. The company is headquartered in Jupiter, Florida. The firm focuses on applications for its technologies to dental care, wound healing, thrombosis and other tissue preserving uses. Its products include Krillase and DuraGraft. Krillase, is a medical device for treating chronic wounds. Its Krillase pipeline includes MB101 and MB104. MB101 is being developed as a therapy for complex wounds and burns. MB104 is being developed as a therapy for deep vein thrombosis. DuraGraft is a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, thereby reducing the incidence and complications of graft failure and improving clinical outcomes post bypass surgery.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 5 Apr 1995
- Employees
- 249
- Website
- marizyme.com ↗
Leadership
Pay as last reported
- Dr. Vithalbhai DhadukIndependent Chairman of the Board, since 2021$76,000
- Mr. David BarthelChief Executive Officer, Secretary, Director, since 2021$350,000
- Mr. George KovalyovChief Financial Officer, Treasurer$168,000
- Dr. Catherine PachukExecutive Vice President, Chief Scientific Officer$325,000
- Mr. Harrison RossVice President - Finance
- Mr. Terry BrostowinIndependent Director$56,000
- Dr. Nilesh PatelIndependent Director$36,000
- Mr. Michael StewartIndependent Director$56,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Marizyme Inc has a strong portfolio of innovative enzymatic products that provide unique solutions in various industries. These products are often more effective and eco-friendly compared to traditional chemical alternatives, giving the company a competitive advantage.
- The company's strong research and development capabilities allow for continuous product improvement and potential expansion into new markets. Marizyme Inc's team of experienced scientists and engineers ensures the development of cutting-edge enzymatic technologies.
Weaknesses
- Marizyme Inc relies heavily on its intellectual property rights, and any potential infringement or legal challenges could impact the company's competitive position. Additionally, the high costs associated with research and development contribute to financial constraints that may limit rapid expansion.
- The company's relatively small market presence compared to larger competitors can also pose challenges in terms of market penetration and brand recognition. Limited resources for marketing and distribution might hinder the company's ability to reach a wider customer base.
Opportunities
- The growing trend towards sustainable and eco-friendly solutions presents a significant opportunity for Marizyme Inc. Increased awareness and demand for environmentally conscious products provide a market space for the company's enzymatic technologies, allowing them to gain a competitive edge.
- Marizyme Inc can explore strategic partnerships and collaborations with industry leaders or academic institutions to leverage their expertise and expand the application of their enzymatic products. These partnerships can also open doors to new markets and provide access to additional resources.
Threats
- The existence of substitute products in the market poses a threat to Marizyme Inc. Competitors offering alternative solutions, including chemical-based products or other enzymatic technologies, may challenge the company's market share if they can offer similar performance and cost-effectiveness.
- Marizyme Inc is also exposed to economic fluctuations and regulatory changes. Economic downturns can impact customer spending, potentially affecting product demand. Moreover, evolving regulations regarding product safety and environmental standards could require additional compliance efforts and potentially impact the company's operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.